Who Is Driving The Bus - Drug Developers & Healthcare Providers or AI?
BioSpace · BioSpace
Audio is streamed directly from the publisher (api.riverside.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This is the third episode of Denatured's discussion on diversity, equity and inclusion (DE&I).
AI represents unlimited opportunities to increase efficiency, but as our guests note, it can also do incredible harm to patients and society. It largely comes down to training of the professionals using AI, as well as understanding how the AI model was grounded or trained. The data quality must be accurate and clean, but as they noted, DE&I is an issue the industry has been struggling with for decades.
The solution lies in humans identifying problems, such as the lack of patient diversity in data, as well as studies in certain disease states, such as HPV-derived cancers. Going further, it is up to the industry to collaborate with each stake holder within the life sciences and healthcare spaces to use AI in ways that are patient focused.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Dr. Ali Pashazadeh, CEO,Treehill Partners
Dr. Charlotte Jones-Burton, Board Member, bluebird bio; Founder & President, Women of Color in Pharma
Chia Chia Sun, Chief Commercial Officer, Fab Biopharma; CEO, Damiva
Phyllis Greenberger, Senior Vice President, Policy & Regulatory, Healthy Women
Dr. Todd Rudo, Chief Medical Officer, Clario